BrightGene Resubmits Hong Kong IPO Application

MT Newswires Live05-19

BrightGene Bio-Medical Technology (SHA:688166) has resubmitted its application to launch an initial public offering on the Hong Kong Stock Exchange.

The pharmaceutical company filed a new draft application on Monday, according to a Tuesday filing with the Shanghai bourse.

The proposed listing still requires regulatory approvals, including from the China Securities Regulatory Commission and Hong Kong's Securities and Futures Commission.

BrightGene plans to use a portion of the proceeds for research and development of its products, including its BGM0504 injection for the treatment of obesity.

Huatai International is the sole sponsor of the proposed IPO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636883724?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636883724","market":"nz","top_or_hot":-1,"title":"BrightGene Resubmits Hong Kong IPO Application","media":"MT Newswires Live","content":"<html><body><p> BrightGene Bio-Medical Technology (SHA:688166) has resubmitted its application to launch an initial public offering on the Hong Kong Stock Exchange.</p><p>The pharmaceutical company filed a new draft application on Monday, according to a Tuesday filing with the Shanghai bourse.</p><p>The proposed listing still requires regulatory approvals, including from the <a href=\"https://laohu8.com/S/601066\">China Securities</a> Regulatory Commission and Hong Kong's Securities and Futures Commission.</p><p>BrightGene plans to use a portion of the proceeds for research and development of its products, including its BGM0504 injection for the treatment of obesity.</p><p>Huatai International is the sole sponsor of the proposed IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BrightGene Resubmits Hong Kong IPO Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrightGene Resubmits Hong Kong IPO Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-19 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BrightGene Bio-Medical Technology (SHA:688166) has resubmitted its application to launch an initial public offering on the Hong Kong Stock Exchange.</p><p>The pharmaceutical company filed a new draft application on Monday, according to a Tuesday filing with the Shanghai bourse.</p><p>The proposed listing still requires regulatory approvals, including from the <a href=\"https://laohu8.com/S/601066\">China Securities</a> Regulatory Commission and Hong Kong's Securities and Futures Commission.</p><p>BrightGene plans to use a portion of the proceeds for research and development of its products, including its BGM0504 injection for the treatment of obesity.</p><p>Huatai International is the sole sponsor of the proposed IPO.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636883724","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636883724","pubTimestamp":1779154671,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BrightGene Bio-Medical Technology (SHA:688166) has resubmitted its application to launch an initial public offering on the Hong Kong Stock Exchange.The pharmaceutical company filed a new draft applica","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688166":"博瑞医药","IPOS":"Renaissance International IPO ETF","SPCX":"SPAC and New Issue ETF","BK0239":"医药制造"},"translate_title":"BrightGene重新提交香港IPO申请","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688166":0.9,"IPOS":1.5,"SPCX":1.5},"content_text":"BrightGene Bio-Medical Technology (SHA:688166) has resubmitted its application to launch an initial public offering on the Hong Kong Stock Exchange.The pharmaceutical company filed a new draft application on Monday, according to a Tuesday filing with the Shanghai bourse.The proposed listing still requires regulatory approvals, including from the China Securities Regulatory Commission and Hong Kong's Securities and Futures Commission.BrightGene plans to use a portion of the proceeds for research and development of its products, including its BGM0504 injection for the treatment of obesity.Huatai International is the sole sponsor of the proposed IPO.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636883724","isCrawlerRequest":true}